Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma

Next Previous
Trial Profile

A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYT 001 (Primary) ; Eftilagimod alpha (Primary) ; Poly ICLC (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms CRESCENT 1

    • Most Recent Events

    • 17 Mar 2023 Results assessing safety of therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma published in the Hepatology Research
    • 19 May 2021 Status changed from recruiting to active, no longer recruiting.
    • 22 Jun 2020 According to a CYTLIMIC media release, the inclusion of patients will be continued at Yamaguchi University Graduate School of Medicine, until the end of September 2020 or the number of included patients reaches 20.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top